Publication | Closed Access

Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer—A phase I toxicity study and pharmacokinetic analysis

Pharmacokinetic AnalysisMedicineImmunologyRecombinant Human Interleukin-4Immune Checkpoint InhibitorRhu Il-4Metronomic ChemotherapyImmunotherapyOncologyRadiation OncologyCancer Research